DeCure for Spondyloepimetaphyseal dysplasia with joint laxity
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for spondyloepimetaphyseal dysplasia with joint laxity — screening already-approved drugs against its 6-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleSpondyloepimetaphyseal dysplasia with joint laxity maps to a 6-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for spondyloepimetaphyseal dysplasia with joint laxity is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
kinesin family member 22 (KIF22) — KIF22 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6NJE · 2.2 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
Spondylo-epi-metaphyseal dysplasia with joint laxity (SEMDJL) is an autosomal recessive skeletal dysplasia. In an analysis of 18 affected persons from 13 Afrikaner families in South Africa, survival into adulthood was unusual. A later report described a single patient who required multiple operative procedures and had the longest reported follow-up and survival into adulthood with a favourable outcome. A Brazilian case was reported in 1996 as the first non-Afrikaner patient with the condition; before that report the disorder had been described only in 20 children of Afrikaans-speaking parents in South Africa.
The condition is characterised by severe dwarfism, generalised articular hypermobility, and progressive spinal malalignment. There is a propensity to joint dislocation and subluxation, and a typical facies. The progressive spinal malalignment can lead to profound disability with potentially lethal spinal and pulmonary complications in early childhood. The 2003 report states that diagnostic precision is of vital importance because the disorder is currently believed to be more common than initially reported.
No drug treatment is mentioned in any of these abstracts. No trial of any pharmacological intervention has been reported. The natural history data come from fewer than 40 patients total, most from a single South African population.
What is missing is any clinical trial of a drug, any funding for such a trial, any identified molecular target, and any patient stratification beyond the clinical diagnosis. The disorder remains defined by its skeletal and orthopaedic features, with no therapy described beyond surgical management of complications.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Clinical Genetics · 1984 · 43 citations
The manifestations and natural history of spondylo‐epi‐metaphyseal dysplasia with joint laxity
AbstractSpondylo-epi-metaphyseal dysplasia with joint laxity (SEMDJL) is characterized by severe dwarfism, articular hypermobility and progressive spinal malalignment. The clinical manifestations of 18 affected persons in 13 families of the Afrikans-speaking community of South Africa have been analysed and it has become evident that survival into adulthood is unusual. SEMDJL is inherited as an autosomal recessive trait.
American Journal of Medical Genetics Part A · 2003 · 11 citations
Spondyloepimetaphyseal dysplasia with joint laxity (SEMDJL)
AbstractSpondyloepimetaphyseal dysplasia with joint laxity (SEMDJL) is a distinctive form of skeletal dysplasia characterized by severe dwarfism, generalized articular hypermobility, and progressive spinal malalignment. We report on a patient with SEMDJL, who presented with all the characteristic orthopedic manifestations of the disorder, required multiple operative procedures, and has the longest reported follow-up and survival into adulthood with a favorable outcome. We describe all the clinical and radiographic findings that can allow an early diagnosis of this type of skeletal dysplasia, which can lead to profound disability with potentially lethal spinal and pulmonary complications in early childhood. In view of the severe clinical and genetic implications, diagnostic precision is of vital importance, particularly since the disorder is currently believed to be more common than initially reported.
American Journal of Medical Genetics · 1996 · 6 citations
Spondyloepimetaphyseal dysplasia with joint laxity (SEMDJL): A Brazilian case
AbstractThis is a report on a Brazilian patient with spondyloepimetaphyseal dysplasia with joint laxity (SEMDJL; MIM 271640), a rare autosomal recessive skeletal dysplasia characterized by dwarfism, articular hypermobility, progressive intractable spinal malalignment, a typical facies and a propensity to joint dislocation and subluxation. The condition has been described only in 20 children of Afrikaans-speaking parents in South Africa. This is the first report of a non-Afrikaans patient with this genetic entity.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
